Compare MHH & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | IMA |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 66.3M |
| IPO Year | 2008 | 2021 |
| Metric | MHH | IMA |
|---|---|---|
| Price | $6.34 | $3.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | $12.75 | ★ $18.00 |
| AVG Volume (30 Days) | 7.0K | ★ 9.4K |
| Earning Date | 10-30-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,371,000.00 | $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.94 | N/A |
| P/E Ratio | $627.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.50 | $3.34 |
| 52 Week High | $8.37 | $7.89 |
| Indicator | MHH | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 23.89 |
| Support Level | $6.24 | N/A |
| Resistance Level | $6.84 | $6.13 |
| Average True Range (ATR) | 0.32 | 0.24 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 10.35 | 5.55 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.